Literature DB >> 10989819

Changing patterns of infections and antimicrobial susceptibilities.

G Maschmeyer1, G A Noskin, P Ribaud, K A Sepkowitz.   

Abstract

Nosocomial bloodstream infections across the United States and in Europe are increasingly attributable to gram-positive species--a trend that represents a reversal of the gram-negative predominance of the previous decades. Data from Memorial Sloan-Kettering Cancer Center and elsewhere show that patients with hematologic malignancies or patients who are immunocompromised because of anticancer treatments are experiencing this shift in microbial spectrum. Most common among gram-positive species are coagulase-negative Staphylococci. Antimicrobial resistance continues to increase, which makes treatment more difficult for infections caused by some species, especially vancomycin-resistant enterococcal species. The underlying causes of changes in microbial spectrum and drug-resistance patterns are incompletely understood, but it is clear that antibiotic exposure exerts a significant selective pressure on pathogens, resulting in partial or complete resistance. New drugs or drug combinations will be necessary to treat drug-resistant infections in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10989819

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  2 in total

1.  Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection.

Authors:  Phillip H A Lee; Takaaki Ohtake; Mohamed Zaiou; Masamoto Murakami; Jennifer A Rudisill; Kenneth H Lin; Richard L Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

2.  Evaluation of a fully automated system (RAISUS) for rapid identification and antimicrobial susceptibility testing of Staphylococci.

Authors:  K Kanemitsu; H Kunishima; M Hatta; K Inden; T Saga; H Ouchi; K Ishizawa; H Harigae; H Takemura; M Kaku
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.